Interview with Dr. David Yang, President, MicroConstants China
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Address: Suite 1-201, Building 18
99 Kechuang 14th Street
BDA, Beijing 101111
P.R.China
Tel: +86 (10) 59776728
Web: http://www.microconstants.com.cn/
MicroConstants China is a Contract Research Organization (CRO) that provides premier quality bioanalytical services, integrated clinical trial management services，IND-enabling drug metabolism (DMPK) assays, pharmacokinetic analysis, ELISA immunoassay, biomarker analysis, and quality system consulting to pharmaceutical/biotech companies and research institutes worldwide. Our in-house OECD GLP compliant bioanalytical laboratory specializes in method development, method validation, and sample analysis of small molecules, proteins, and peptides using LC/MS/MS, HPLC/UV, and ELISA for preclinical and clinical PK samples.
Our mission is to provide GLP/GCP compliant preclinical and clinical contract service in China to meet global product registration requirement.
Our goal is to conduct contract research service according to global recognized quality standards to ensure data integrity, accuracy, traceability and safety. Through vigorous audit of data, qualification and training of our partnering clinical site, open communication and quick resolve of our clients’ concern, we expedite our clients drug development process by providing data that meet various regulatory agencies requirement.
Although MicroConstants traces its history back to 1998 in San Diego, you co-founded the China operations in 2007. What’s the story behind how that came about? It all began when…
Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it…
Dr Tianyi (Tee) Zhang, GM of Frontage China and SVP of Frontage Holdings, shares the significant growth of the China affiliate over the past four years; their competitive advantages in…
Dr Jiang Lei and Dr Shou Jianyong, EnnovaBio’s co-founders, introduce their strategy and outline the progress being made in the Chinese biopharma industry at large. We are a Chinese…
Dr Shun Luo, chairman, founder and CEO of Thousand Oaks Biopharmaceuticals, shares the company’s vision to deliver more accessible and affordable biologics to patients globally by lowering the cost of…
Catherine Lee, general manager and managing director of West Pharmaceutical Services China, shares the highlights of her 2.5 years heading West’s China affiliate; West’s commitment to delivering their global scientific…
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Dr Jinzi Jason Wu of Ascletis – a Chinese biotech success story that has developed rapidly in recent years – outlines the company’s journey from its founding in 2013 to…
PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in…
More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the…
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
See our Cookie Privacy Policy Here
